Evidence map›Paper›PMID 38022656›Full record

ArticleFrontiers in immunology2023

Comparison of peripheral leukocyte parameters in patients receiving conventionally and hypofractionated radiotherapy schemes for the treatment of newly diagnosed glioblastoma.

Lindsey Greenlund, Ryan Shanley, Kellen Mulford, Elizabeth C Neil, Jessica Lawrence, Susan Arnold, Michael Olin, G Elizabeth Pluhar, Andrew S Venteicher, Clark C Chen and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Lindsey GreenlundDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
Ryan ShanleyClinical and Translational Science Institute, University of Minnesota, Minneapolis, MN, United States.
Kellen MulfordDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
Elizabeth C NeilMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Jessica LawrenceMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Susan ArnoldMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Michael OlinMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
G Elizabeth PluharMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Andrew S VenteicherMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Clark C ChenDepartment of Neurosurgery, University of Minnesota, Minneapolis, MN, United States.
Clara FerreiraDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
Margaret ReynoldsDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
L Chinsoo ChoDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
Christopher WilkeDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
B Aika ShooDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
Jianling YuanDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
Kathryn DusenberyDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
Lawrence R KleinbergDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Stephanie A TerezakisDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
Lindsey SloanDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN, United States.
University of Minnesota · USUniversity of Minnesota Medical Center · USJohns Hopkins Medicine · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Project 3P01CA254849 · NCI · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S · 2021 to 2025
$9.4M
TECH CoreU54CA268069 · NCI · UNIVERSITY OF MINNESOTA · PI Kevin William Eliceiri, Paolo Provenzano · 2022 to 2026
$8.2M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P01 CA254849NCI NIH HHS P30 CA077598NCI NIH HHS U54 CA268069
6 · The paper itself

Abstract

Introduction: Treatment for glioblastomas, aggressive and nearly uniformly fatal brain tumors, provide limited long-term success. Immunosuppression by myeloid cells in both the tumor microenvironment and systemic circulation are believed to contribute to this treatment resistance. Standard multi-modality therapy includes conventionally fractionated radiotherapy over 6 weeks; however, hypofractionated radiotherapy over 3 weeks or less may be appropriate for older patients or populations with poor performance status. Lymphocyte concentration changes have been reported in patients with glioblastoma; however, monocytes are likely a key cell type contributing to immunosuppression in glioblastoma. Peripheral monocyte concentration changes in patients receiving commonly employed radiation fractionation schemes are unknown. Methods: To determine the effect of conventionally fractionated and hypofractionated radiotherapy on complete blood cell leukocyte parameters, retrospective longitudinal concentrations were compared prior to, during, and following standard chemoradiation treatment. Results: This study is the first to report increased monocyte concentrations and decreased lymphocyte concentrations in patients treated with conventionally fractionated radiotherapy compared to hypofractionated radiotherapy. Discussion: Understanding the impact of fractionation on peripheral blood leukocytes is important to inform selection of dose fractionation schemes for patients receiving radiotherapy.

Indexed as

GlioblastomaHumansLeukocytesRadiation Dose HypofractionationRetrospective StudiesTreatment OutcomeTumor Microenvironmentconventionally fractionated radiotherapyfractionationglioblastomahypofractionated radiotherapyleukocytes

Identifiers

PMID38022656
PMCPMC10644882
OpenAlexW4388194758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.